Taking a daily low-dose aspirin increases the chance of serious bleeding in healthy older adults by nearly 40% compared to not taking it, with no offsetting benefit to health or independence.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of all RCTs of low-dose aspirin in elderly populations would definitively quantify the pooled risk of major hemorrhage and determine if this risk is consistent across age groups and baseline risk profiles.
A systematic review and meta-analysis of all randomized controlled trials comparing daily low-dose aspirin (75–100 mg) to placebo in adults aged 65 or older without cardiovascular disease, with major hemorrhage as a pre-specified safety outcome, using individual participant data to adjust for age, sex, and comorbidities, and pooling hazard ratios with random-effects models.
A new RCT with longer follow-up could confirm whether the increased hemorrhage risk persists beyond 5 years and whether it is dose-dependent or modified by age or frailty.
A double-blind, placebo-controlled RCT of 10,000 healthy adults aged 70–85, randomized to 100 mg aspirin or placebo daily, with primary safety outcome of major hemorrhage (defined as intracranial, gastrointestinal, or other life-threatening bleeding) over 7 years, using blinded adjudication and mandatory reporting of all bleeding events.
A prospective cohort could estimate the real-world incidence of major hemorrhage in elderly aspirin users over time, adjusting for concomitant medications and comorbidities.
A prospective cohort study following 25,000 adults aged 70+ in primary care databases for 10 years, tracking aspirin use (dose, duration), major hemorrhage events (via hospital records and death registries), and adjusting for anticoagulant use, NSAID use, hypertension, and renal function.
A case-control study could assess whether prior aspirin use is associated with specific types of hemorrhage (e.g., intracranial, GI) in elderly patients presenting with bleeding events.
A case-control study comparing 1,500 elderly patients hospitalized for major hemorrhage (intracranial, GI, or other) to 1,500 matched controls without bleeding, using pharmacy records and structured interviews to assess aspirin use in the 6 months prior to event, adjusting for age, sex, and anticoagulant use.
A cross-sectional survey could estimate the prevalence of recent bleeding events among elderly aspirin users at a single point in time.
A cross-sectional survey of 10,000 adults aged 70+ in community settings, asking about recent (past 12 months) major bleeding events and current aspirin use, with adjustment for age, sex, and comorbidities.